Intestinal Metaplasia
40
6
7
17
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.0%
2 terminated out of 40 trials
89.5%
+3.0% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (40)
Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis
Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy
Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)
UC Davis Cohort of Pre-Malignant and Malignant Gastro-Intestinal DisEases Study
Acetic Acid for the Detection of Esophageal Neoplasms
Atrophic Gastritis and OLGIM Stage
Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis
A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions
Evaluation of Antral Biopsies Obtained in Normal Esophagogastroduodenoscopy
Systems Biology of Gastrointestinal and Related Diseases
The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
Intestinal Flora and Metabonomics of Appendicitis
AG & IM in CA Stomach Protocol
The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE
Effect of H. Pylori Eradication on the Reversibility of Atrophic Gastritis and Intestinal Metaplasia in Korean Patients
OLGA and OLGIM Stage System for Gastric Cancer
Artificial Intelligence for Determination of Gastroscopy Surveillance Intervals
Artificial Intelligence-assisted Confocal Laser Endomicroscopy Identification of Intestinal Metaplasia Severity
SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up